These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 175391)

  • 1. Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.
    Cools AR; Van Rossum JM
    Psychopharmacologia; 1976 Feb; 45(3):243-54. PubMed ID: 175391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evidence about nigro-striatal inhibition related to intrinsic GABA in the caudate nucleus deprived of dopaminergic synaptic activity.
    Feltz P
    Appl Neurophysiol; 1979; 42(1-2):47-50. PubMed ID: 222207
    [No Abstract]   [Full Text] [Related]  

  • 3. Substantia nigra as a station that not only transmits, but also transforms, incoming signals for its behavioural expression: striatal dopamine and GABA-mediated responses of pars reticulata neurons.
    Cools AR; Jaspers R; Kolasiewicz W; Sontag KH; Wolfarth S
    Behav Brain Res; 1983 Jan; 7(1):39-49. PubMed ID: 6297521
    [No Abstract]   [Full Text] [Related]  

  • 4. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

  • 5. Unilateral 6-hydroxydopamine lesions of nigrostriatal or mesolimbic dopamine-containing terminals and the drug-induced rotation of rats.
    Kelly PH
    Brain Res; 1975 Dec; 100(1):163-9. PubMed ID: 1237342
    [No Abstract]   [Full Text] [Related]  

  • 6. Some neuroactive compounds in the substantia nigra.
    Krnjević K
    Adv Neurol; 1974; 5():145-52. PubMed ID: 4155230
    [No Abstract]   [Full Text] [Related]  

  • 7. Electrophysiological and pharmacological characterization of identified nigrostriatal and mesoaccumbens dopamine neurons in the rat.
    Clark D; Chiodo LA
    Synapse; 1988; 2(5):474-85. PubMed ID: 2903568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine receptors: selective agonists and antagonists of functionally distinct types within the feline brain.
    Cools AR; Boudier AJ; Rossum JM
    Eur J Pharmacol; 1976 Jun; 37(2):283-93. PubMed ID: 986303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ergot alkaloids as dopamine agonists: comparison in two rodent models.
    Anlezark G; Pycock C; Meldrum B
    Eur J Pharmacol; 1976 Jun; 37(2):295-302. PubMed ID: 986304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piribedil and apomorphine: pre- and postsynaptic effects on dopamine synthesis and neuronal activity.
    Walters JR; Bunney BS; Roth RH
    Adv Neurol; 1975; 9():273-84. PubMed ID: 167566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors.
    Cools AR; van Rossum JM
    Life Sci; 1980 Oct; 27(14):1237-53. PubMed ID: 6255271
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo presynaptic control of dopamine release in the cat caudate nucleus--I. Opposite changes in neuronal activity and release evoked from thalamic motor nuclei.
    Romo R; Chéramy A; Godeheu G; Glowinski J
    Neuroscience; 1986 Dec; 19(4):1067-79. PubMed ID: 3029624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional aspects of, and the role of transmitter in, the basal ganglia.
    Yoshida M
    Confin Neurol; 1974; 36(4-6):282-91. PubMed ID: 4156664
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitory mechanisms in the substantia nigra and the dopamine pathway.
    Straughan DW; James TA
    Int J Neurol; 1979; 13(1-4):81-93. PubMed ID: 122391
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
    Koltai MZ; György L
    Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo presynaptic control of dopamine release in the cat caudate nucleus--III. Further evidence for the implication of corticostriatal glutamatergic neurons.
    Romo R; Chéramy A; Godeheu G; Glowinski J
    Neuroscience; 1986 Dec; 19(4):1091-9. PubMed ID: 2881228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The susceptibility to acetylcholine and dopamine in the caudate nucleus of cats with chronic nigrostriatal lesions.
    Sphelmann R
    Trans Am Neurol Assoc; 1974; 99():255-7. PubMed ID: 4156892
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo voltammetric study of dopamine release in the striatum following microinjection of apomorphine into the substantia nigra zona reticulata.
    Kamata K; Sugimoto A; Kameyama T
    Jpn J Pharmacol; 1986 Mar; 40(3):472-7. PubMed ID: 3712872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inputs to nigra neurons from caudate nucleus and fundus striati.
    Wagner A; Paik KS
    Appl Neurophysiol; 1979; 42(1-2):34-6. PubMed ID: 453802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.